2026年2月27日,默沙东股价单日涨3.79%至123.82美元,其所属“抗癌医药”板块整体上涨2.68%。股价上涨或受多方面因素影响:当日“抗癌医药”板块表现强劲,多数成分股上涨,默沙东作为代表公司受益;2月26日默沙东宣布抗病毒药物普瑞明三种剂型获中国国家药监局批准,新增儿童用药方案,利好消息次日继续提振市场信心;同日公司宣布范柏睿将任默沙东印度公司董事总经理,市场视为强化重点市场战略的积极...
Source Link2026年2月27日,默沙东股价单日涨3.79%至123.82美元,其所属“抗癌医药”板块整体上涨2.68%。股价上涨或受多方面因素影响:当日“抗癌医药”板块表现强劲,多数成分股上涨,默沙东作为代表公司受益;2月26日默沙东宣布抗病毒药物普瑞明三种剂型获中国国家药监局批准,新增儿童用药方案,利好消息次日继续提振市场信心;同日公司宣布范柏睿将任默沙东印度公司董事总经理,市场视为强化重点市场战略的积极...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.